- Home
- FLC vs INBX Comparison
FLC vs INBX Comparison
Compare FLC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | INBX |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLC | INBX |
|---|---|---|
| Price | $17.40 | $75.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.8K | ★ 236.0K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.62 | $10.81 |
| 52 Week High | $15.45 | $94.47 |
Technical Indicators
Market Signals| Indicator | FLC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 46.07 |
| Support Level | $17.23 | $79.00 |
| Resistance Level | $17.50 | $94.47 |
| Average True Range (ATR) | 0.13 | 5.90 |
| MACD | 0.00 | -2.08 |
| Stochastic Oscillator | 47.57 | 5.29 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.